Thrombopoetin Receptor Agonist Therapy in Thrombocytopenia: ITP and Beyond

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.14564
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Switching Thrombopoietin Receptor Agonist Treatments in Patients With Primary Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2019English

A United Kingdom Immune Thrombocytopenia (ITP) Forum Review of Practice: Thrombopoietin Receptor Agonists

British Journal of Haematology
Hematology
2016English

Highly Fluctuating Thrombocytopenia Developing in a Patient With Immune Thrombocytopenia (ITP) While Administering Romiplostim

Internal Medicine
Internal MedicineMedicine
2012English

An Update on the Immunopathology of Immune Thrombocytopenia (ITP)

Pathology
Forensic MedicinePathology
2020English

Deciphering Predictive Factors for Choice of Thrombopoietin Receptor Agonist, Treatment Free Responses, and Thrombotic Events in Immune Thrombocytopenia

Scientific Reports
Multidisciplinary
2019English

Authors’ Reply Re: Severe Primary Autoimmune Thrombocytopenia (ITP) in Pregnancy: A National Cohort Study

BJOG: An International Journal of Obstetrics and Gynaecology
GynecologyObstetrics
2017English

P340 Case Report: Immune Thrombocytopenia Purpura (ITP) – An Intra-Oral and Extra-Oral Presentation

2019English

Eltrombopag: An Update on the Novel, Non-Peptide Thrombopoietin Receptor Agonist for the Treatment of Immune Thrombocytopenia

Annals of Hematology
MedicineHematology
2010English

Eltrombopag, a Thrombopoietin- Receptor Agonist in the Treatment of Adult Chronic Immune Thrombocytopenia: A Review of the Efficacy and Safety Profile

Therapeutic Advances in Hematology
Hematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy